Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.67 |
| ▸ | TNF | P01375 | 4/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.58 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lisofylline, (S)- SCHEMBL1495100 | 1.00 | ADORA2B (0.67) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL39131 | 1.00 | ADORA2B (0.67) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6778207 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6778919 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6777369 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8699282 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6783783 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8700060 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6774460 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL10517408 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1759 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-11345956-B2 | Methods and compositions related to prostate cancer therapeutics | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-31 | — | — | US | claimed |
| US-6710051-B1 | SUBSTANCES IS A XANTHINE AND IS ADMINISTERED IN A DOSAGE OF 7.5-750 MG 1-4 TIMES DAILY TO TREAT MYOPIA | KLAUS TRIER APS (DK) | 2004-03-23 | — | — | US | claimed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| EP-0584347-B1 | ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS | CELL THERAPEUTICS INC (US) | 2003-01-15 | — | — | EP | claimed |
| US-6294350-B1 | TREATING DISEASE CHARACTERIZED BY INCREASED LEVELS OF C-JUN HOMODIMERS, INCREASED HETERODIMERIZATION OF C-JUN WITH ANOTHER SIGNALING PEPTIDE, INCREASED LEVELS OF PHOSPHORYLATED C-JUN, AND/OR INCREASED PRESENCE OF JUN KINASE | DALHOUSIE UNIVERSITY (CA) | 2001-09-25 | — | — | US | claimed |
| WO-2001032156-A2 | METHODS FOR TREATING FIBROPROLIFERATIVE DISEASES | DALHOUSIE UNIVERSITY (CA) | 2001-05-10 | — | — | WO | claimed |
| WO-2000066101-A2 | METHOD OF INHIBITING GLYCATION PRODUCT FORMATION | CITY OF HOPE (US) | 2000-11-09 | — | — | WO | claimed |
| US-5112827-A | Purine derivatives, pentoxifylline, anticholesterol, arterial antideposit agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-05-12 | — | — | US | claimed |
| EP-0462506-A1 | Pharmaceutical preparations of mixtures comprising cefotaxim and derivatives of xanthine and their use | Schrinner, Elmar J., Dr. (DE) | 1991-12-27 | — | — | EP | claimed |
| EP-0169466-B1 | MIXTURE OF XANTHIN DERIVATIVES AND O-ACETYL-SALICYLIC ACID, OR THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS, AND ITS USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-04-04 | — | — | EP | claimed |
| US-4880791-A | BLOOD DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-11-14 | — | — | US | claimed |
| EP-0305743-A2 | Pharmaceutical mixture preparation, its manufacture and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-03-08 | — | — | EP | claimed |
| US-4636507-A | Host defense mechanism enhancement | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-01-13 | — | — | US | claimed |
| US-4576947-A | HYDROXYALKYLXANTHINES, INCREASING CEREBRAL BLOOD FLOW, BRONCHODILATORS | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-03-18 | — | — | US | claimed |
| EP-0169466-A2 | Mixture of xanthin derivatives and O-acetyl-salicylic acid, or their pharmacologically acceptable salts, and its use | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-01-29 | — | — | EP | claimed |
| US-4515795-A | INSUFFICIENCY OF CEREBRAL BLOOD FLOW | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-05-07 | — | — | US | claimed |
| US-4189469-A | Pharmaceutical compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC3, HDAC1, HDAC4 | ADORA2B 1595/4885TNF 4596/4885USP2 2840/4885 |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | ADORA2B 826/4885TNF 1783/4885USP2 2776/4885 |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC7, HDAC5 | ADORA2B 3296/4885TNF 3852/4885USP2 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.